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During pregnancy, many women experience sleep problems and anxiety that require treat-
ment. The long-term safety for the child of maternal benzodiazepine (BZD) and z-hypnotic
use during pregnancy remains controversial.
Method
We conducted a cohort and a sibling control study using data from the Norwegian Mother
and Child Cohort Study. Data on use of BZD and z-hypnotics, internalizing and externalizing
outcomes, and covariates were collected from mothers at gestational weeks 17 and 30 and
when children were 0.5, 1.5, and 3 years of age. The total sample consisted of 71,996 chil-
dren (19,297 siblings) at 1.5 years and 55,081 children (13,779 siblings) at 3 years. Short-
term use was defined as use in one pregnancy period only. Long-term use was defined as
use in two or more pregnancy periods. Linear full cohort random-effect and sibling-matched
fixed-effect regression models were used to compare internalizing and externalizing
behavior in children prenatally exposed compared to those unexposed in the full cohort of
pregnancies accounting for family clusters, as well as within sibling clusters comparing preg-
nancies with discordant exposures. Propensity score (PS) adjustment included variables on
indication for use (sleep problems, symptoms of anxiety and depression) and other potential
confounding factors.
Results
Long-term prenatal exposure to BZD or z-hypnotics was associated with increased internal-
izing behavior in crude cohort analyses and at age 1.5 years after PS adjustment in sibling-
matched fixed-effect models [β 0.60, 95% confidence interval 0.17–0.95]. Analyses on spe-
cific drug groups showed that prenatal exposure to BZD-anxiolytics was associated with
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increased internalizing problems at both 1.5 years [β 0.25, 0.01–0.49] and 3 years [β 0.26,
0.002–0.52] while exposure to z-hypnotics was not associated with any adverse outcomes
after adjustment.
Conclusion
The findings suggest a moderate association between BZD-anxiolytic exposure and child
internalizing problems that is not likely due to stable familial confounding factors.
Introduction
Up to 20% of women are estimated to experience sleep problems and symptoms of anxiety
during pregnancy [1, 2]. Between 1 and 3% of Norwegian women use benzodiazepine (BZD)
or z-hypnotic drugs to treat anxiety disorders or insomnia while pregnant [3]. These medica-
tions have sedative, hypnotic, anxiolytic, anticonvulsant, and muscle-relaxing effects depend-
ing primarily on how long they act on the gamma-aminobutyric acid (GABAA) receptor [4].
BZDs and z-hypnotics cross the placenta and have the potential to bind to receptors in the
developing embryonal/fetal central nervous system [5]. It has been proposed that exposure to
medications that mimic GABA at GABAA receptors also trigger apoptotic neurodegeneration
in the developing brain [6].
In the 1980s, a number of rat studies consistently showed that prenatal exposure to BZDs
resulted in behavioral deficits and altered brain function [7–11]. Withdrawal syndrome and
floppy infant syndrome have been reported in babies after maternal use of BZDs towards the
end of pregnancy [12–15]. Results of previous studies on mental health outcomes in the off-
spring following prenatal exposure to BZDs or z-hypnotic drugs have been conflicting [16–
18]. A sibling-matched study found no association with behavioral deviation in children at age
8–12 months after prenatal exposure to medazepam [16]. In contrast, a study on 1.5-year-old
children showed reduced personal-social behavior abilities in children exposed to BZDs [17].
The only published investigation of behavioral outcomes in children older than 1.5 years fol-
lowing prenatal exposure to BZDs was a retrospective study based on 15 exposed children,
which found no effects on behavior at the age of 9–10 years [18]. None of these studies con-
trolled for indication for use in the mother.
Well-designed observational studies and randomized controlled trials (RCTs) have been
called for to resolve these conflicting findings [19], but because RCTs involving pregnant
women are ethically problematic, observational studies addressing confounding by indication
and other potential confounders take precedent [20]. In this study, using data from the Norwe-
gian Mother and Child cohort study (MoBa), we aimed to evaluate whether prenatal exposure
to BZDs and z-hypnotics affects internalizing or externalizing behavior problems in children
at ages 1.5 and 3 years. Such problems are characterized respectively by negative mood states
and behavioral inhibition and by behavioral disinhibition [21]. Genetic or familial environ-
mental determinants might result in an increased risk of both mood disorders and anxiety in
the mother and behavioral problems in the infant, and living with a mother with these disor-
ders could affect a child’s behavior. To reduce confounding by family conditions, we per-
formed sibling-matched analyses using fixed-effect (FE) models as a conservative approach
to adjust for shared familial confounding. To control for indications that vary over time
and could confound the sibling comparisons, we used propensity scores (PS) to adjust for
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Data were extracted from the ongoing MoBa study conducted by the Norwegian Institute of
Public Health. MoBa is a prospective population-based cohort study following over 100,000
pregnancies [22]. Enrollment in the study started in 1999 and was completed in 2008. The par-
ticipation rate at first assessment was 40.6%. Mothers reported a range of sociodemographic,
medical, and psychological information by filling out questionnaires at gestational weeks (gw)
17 and 30 and at 6, 18, and 36 months postpartum (with response rates of 95%, 92%, 87%,
77%, and 62%, respectively). We used the seventh version of the dataset, which is quality-
assured and was released in 2013 [http://www.fhi.no/moba-en].
The Medical Birth Registry of Norway (MBRN) includes information on pregnancy, deliv-
ery, and neonatal health on all births in Norway [23]. The MoBa and MBRN data were linked
via personal identification numbers.
The research project is approved by the Regional Committees for Medical and Health
Research Ethics (REK) (2015/1897), and the MoBa study has a license from the Norwegian
Data Inspectorate. Written informed consent was obtained from all participants.
Study population
This study was based on data for 71,996 children whose mothers had returned the 1.5-year fol-
low-up questionnaire and 55,081 children whose mothers had returned the 3-year follow-up
questionnaire. Within this cohort, a total of 19,297 siblings were included at 1.5 years and
13,779 siblings at 3 years. All live-born singletons were included in the study population; twins
and triplets (N = 4305) and infants born with major malformations (N = 2970) (Fig 1) were
excluded.
BZD and z-hypnotics exposure
BZDs included drugs classified in Anatomical Therapeutic Chemical (ATC) groups N05BA
(diazepam, oxazepam, alprazolam), N05CD (nitrazepam, midazolam, flunitrazepam),
N03AE01 (clonazepam). Z-hypnotics included drugs classified in the ATC group N05CF
(zopiclone and zolpidem). Drug classification was based on the ATC classification system
developed by the WHO Collaborating Centre for Drug Statistics Methodology [24]. Women
reported information about illnesses they experienced throughout their pregnancy and medi-
cation used for these illnesses in two prenatal (17 gw, 30 gw) and one postnatal questionnaire
(6 months postpartum) covering three time periods: 0 to 13 gw and 14 to 29 gw, and from 30
gw to birth. The women were defined as users of BZDs and z-hypnotics if they had reported
use of any BZD or z-hypnotic drug (ATC groups N05BA, N05CD, N05CF, and N03AE01)
during pregnancy on at least one of the three questionnaires. Short-term use was defined as
reported use in one pregnancy period only (0–13, 14–29, 30–birth), and long-term use was
defined as reported use in two or more pregnancy periods. Separate analyses were also per-
formed for the most commonly reported drug groups: BZD-anxiolytics and z-hypnotics. The
drug groups of BZDs and z-hypnotics used, as well as the number of siblings discordantly
exposed, are described in Table 1.
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Behavior outcomes
The Child Behavior Checklist (CBCL), a validated and widely used measure of child behavior,
was used at 1.5 and 3 years [25]. In MoBa, a shortened version of the CBCL was used; it covers
both externalizing (i.e., aggression, attention problems) and internalizing behavior (i.e., anx-
iousness, emotional reactivity, somatic complaints) and is representative of the full scale [26].
Items were selected by a team of four clinical and developmental psychologists, based on clini-
cal and theoretical standards, as well as empirical representativeness (high factor loadings) for
behavior problems. The questionnaire consisted of 13 items at 1.5 years and 21 items at 3
years, covering externalizing behavior and internalizing behavior. Externalizing behavior was
measured by eight items at 1.5 years and 12 items at 3 years, and internalizing behavior was
measured by five items at 1.5 years and nine items at 3 years. These domains predict later psy-
chopathology in children and adolescents [27]. The questions were answered on a 3-point
scale, as follows: 1 = not true; 2 = somewhat or sometimes true; and 3 = very true or often true.
Fig 1. Flow chart of participants.
https://doi.org/10.1371/journal.pone.0181042.g001
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Mean scores were calculated for externalizing and internalizing behaviors, respectively, and
standardized z-scores then were computed for both behavioral outcomes.
Potential confounders
Confounders were identified by means of a literature review and through use of directed acy-
clic graphs [28] [29] (http://www.dagitty.net/dags.html) [30]. All potential confounders con-
sidered are listed in Tables 2 and 3. Information regarding maternal age and parity was
retrieved from the MBRN. Information on maternal years of formal education, marital status,
pre-pregnancy BMI, sleep problems, chronic disease, and use of folic acid supplements in early
pregnancy was retrieved from the first pregnancy questionnaire. Information on alcohol use,
illicit drug consumption during pregnancy, and smoking was retrieved from all three preg-
nancy questionnaires.
Maternal symptoms of depression and anxiety during the pregnancy were reported via a
validated short version of the Hopkins Symptom Checklist, the SCL-5, at 17 and 30 gw [31].
The 5-item version (SCL-5) has a 0.92 correlation with the original 25-item version. Items in
the SCL are scored on a Likert scale ranging from 1 (not at all bothered) to 4 (very much both-
ered), and scores were calculated as the mean value of the five items. The presence of symp-
toms of anxiety and depression during pregnancy was defined as 85th percentile or above.
Mothers also reported their lifetime history of major depression by answering the lifetime
occurrence of five key depressive symptoms chosen from the nine symptomatic criteria for
Major Depression in the Diagnostic and Statistical Manual of Mental Disorders III, Revised:
sad mood, change in appetite, loss of energy, feelings of guilt or worthlessness, and problems
in concentration. They were then asked whether any three of these symptoms co-occurred in
their life for at least 2 weeks. As previously recommended, individuals who responded posi-
tively to this item and admitted to sad mood were considered to have reported a lifetime his-
tory of major depression [32].
Maternal concomitant use of other drugs (opioids, selective serotonin reuptake inhibitors
(SSRIs), antipsychotics, triptans, nonsteroidal anti-inflammatory drugs (NSAIDs), and para-
cetamol) were reported at 17 and 30 gw and 6 months after birth. Because we previously found
Table 1. Number of pregnant women reporting use of BZDs or z-hypnoticsa.
Drug group Number of children Number of discordant siblings Number of children Number of discordant siblings
1.5 year 1.5 year 3 years 3 years
N = 71,996 (%) Of N = 19,297 N = 55,081 (%) Of N = 13,779
Any benzodiazepine or z-hypnotics 577 (0.80) 183 440 (0.80) 145
Duration of use
Short-term useb 463 (0.64) 157 351 (0.64) 123
Long-term usec 114 (0.16) 26 89 (0.16) 22
Drug subgroups
BZD-anxiolytics 315 (0.44) 108 236 (0.43) 84
BZD-hypnotics 44 (0.06) 12 35 (0.06) 8
BZD-anti-epileptics 19 (0.03) 6 12 (0.02) 8
Z-hypnotics 241 (0.34) 75 192 (0.35) 59
Abbreviations: BZD, benzodiazepines; z-hypnotics, benzodiazepine-related hypnotics
a Some women may have reported use related to several drug groups.
b Short-term use was defined as reported use in one pregnancy period only.
c Long-term use was defined as reported use in two or more pregnancy periods.
https://doi.org/10.1371/journal.pone.0181042.t001
Prenatal exposure to benzodiazepines and child internalizing problems
PLOS ONE | https://doi.org/10.1371/journal.pone.0181042 July 26, 2017 5 / 16
Table 2. Maternal characteristics by use of BZDs and z-hypnotics during pregnancy in the 1.5 year MoBa sample.
Use of BZDs and z-hypnotics
1.5-year sample
No Yes
N = 71,419 N = 557
N % N %
Maternal age in years
<25 6,948 9.7 41 7.1
25–29 23,807 33.3 149 25.8
30–34 28,130 39.4 237 41.1
35 12,534 17.6 150 26.0
Maternal formal education in years
<12 4,229 6.3 55 10.2
12 17,931 26.6 126 23.3
13–16 28,576 42.4 226 41.9
17 16,594 24.7 133 24.6
Marital status
Married or cohabitant 68,416 98.1 518 93.0
Single 1,357 1.9 36 7.0
Maternal BMI
<25 47,712 69.2 398 71.5
25–29 14,936 21.7 111 19.9
30–34 4,618 6.7 41 7.4
35 1,643 2.4 7 1.3
Parity
0 32,999 46.2 282 48.9
1 24,914 34.9 171 29.6
2 13,506 18.9 124 21.5
Maternal smoking
No 66,159 92.6 486 84.2
Yes 5,260 7.4 91 15.8
Maternal alcohol use
No 32,563 45.8 176 30.7
Yes, occasionally 35,958 50.6 340 59.2
Yes, often 2,509 3.6 58 10.1
Maternal symptoms of anxiety/depression 17 gw a
No 67,105 94.0 456 79.0
Yes 4,314 6.0 121 21.0
Maternal symptoms of anxiety/depression 30 gw a
No 67,377 94.3 449 77.8
Yes 4,042 5.7 128 22.2
Lifetime history of major depressionb
No 56,089 78.5 280 48.5
Yes 15,330 21.5 297 51.5
Maternal sleep problems
No 60,361 84.5 328 56.8
Yes 11,058 15.5 249 43.2
Maternal use of illicit drugsc
No 71,205 99.7 538 96.6
(Continued )
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an association between long term paracetamol exposure and behavior problems in the child
we differentiated between short and long term paracetamol use[33].
Statistical methods
First, we used random-effects linear regression models to examine crude effect estimates on
behavior outcomes at 1.5 and 3 years following prenatal exposure to any BZD or z-hypnotics,
short term or long term, for the full MoBa cohort. Random-effects models account for family
clusters in the sample by producing standard errors that adjust for dependence between sib-
lings. Separate analyses were performed for BZD-anxiolytics and z-hypnotics.
Table 2. (Continued)
Use of BZDs and z-hypnotics
1.5-year sample
No Yes
N = 71,419 N = 557
N % N %
Yes 214 0.3 19 3.4
Maternal opioid use in pregnancy
No 70,013 98.0 499 86.5
Yes 1,406 2.0 78 13.5
Maternal SSRI use in pregnancy
No 70,780 99.1 489 84.8
Yes 639 0.9 88 15.3
Maternal antipsychotic use in pregnancy
No 70,780 99.1 489 84.8
Yes 639 0.9 88 15.3
Maternal triptan use in pregnancy
No 70,778 99.1 559 96.9
Yes 641 0.9 18 3.1
Maternal NSAID use in pregnancy
No 66,542 93.2 485 84.1
Yes 4,877 6.8 92 15.9
Maternal use of paracetamol (acetaminophen)
No use 39,294 59.3 224 41.3
1 pregnancy period 24,757 37.3 235 43.4
2 or 3 pregnancy periods 2,244 3.2 83 15.3
Maternal folic acid supplements in early pregnancy
No 22,830 32.0 183 31.7
Yes 48,589 68.0 394 68.3
Maternal chronic diseased
No 64,412 90.2 474 82.2
Yes 7,007 9.8 103 17.8
SSRI, selective serotonin reuptake inhibitors; NSAID, nonsteroidal anti-inflammatory drug
a Mean score of >2 on the Hopkins Symptom Checklist (SCL-5)
b Measured in pregnancy week 17; defined as ever having three co-occurring symptoms of depression for at least 2 weeks and admitting to sad mood
c Illicit drug use included hashish, amphetamine, ecstasy, cocaine, or heroin
d Chronic disease included asthma, diabetes treated with insulin, Crohn’s disease, arthritis, lupus, epilepsy, multiple sclerosis, or cancer
https://doi.org/10.1371/journal.pone.0181042.t002
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Table 3. Maternal characteristics by use of BZDs and z-hypnotics during pregnancy in the 3-year MoBa sample.
Use of BZDs and z-hypnotics
3-year sample
No Yes
N = 54,641 N = 440
N % N %
Maternal age in years
<25 5,058 9.2 31 7.0
25–29 18,170 33.3 117 26.6
30–34 21,720 39.8 175 39.8
35 9,693 17.7 117 26.6
Maternal formal education in years
<12 2,902 5.6 37 9.0
12 13,112 25.4 89 21.5
13–16 22,467 43.5 178 43.1
17 13,164 25.5 109 26.4
Marital status
Married or cohabitant 52,455 98.2 396 93.2
Single 976 1.8 29 6.8
Maternal BMI
<25 36,649 69.4 292 68.9
25–29 11,439 21.7 92 21.7
30–34 3,498 6.6 33 7.8
35 1,249 2.4 7 1.7
Parity
0 25,851 47.3 229 52.0
1 18,889 34.6 120 27.3
2 9,901 18.1 91 20.7
Maternal smoking
No 50,852 93.1 376 85.5
Yes 3,789 6.9 64 14.5
Maternal alcohol use
No 25,671 47.3 147 33.5
Yes, occasionally 26,712 49.2 251 57.2
Yes, often 1,946 3.6 41 9.3
Maternal symptoms of anxiety/depression 17 gw a
No 51,510 94.3 344 78.2
Yes 3,131 5.7 96 21.8
Maternal symptoms of anxiety/depression 30 gw a
No 51,662 94.6 340 77.3
Yes 2,979 5.5 100 22.7
Lifetime history of major depressionb
No 43,096 78.9 213 48.4
Yes 11,545 21.1 227 51.6
Maternal sleep problems
No 46,014 84.2 246 55.9
Yes 8,627 15.8 194 44.1
Maternal use of illicit drugsc
No 51,071 99.8 395 96.8
(Continued )
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Second, we performed PS-adjusted random-effect linear regression analyses by including
PS as covariates in the analyses. PS were determined with logistic regression models within the
complete cohort at 1.5 years and 3 years separately, in which use of any BZD or z-hypnotics
was the outcome variable and the predictors were the variables previously selected (see Tables
2 and 3) as confounders during multivariable model building [34].
Third, we restricted the sample to multiparous mothers and then carried out sibling-
matched FE linear regression using the xtreg function in STATA 14 for FE linear models. As
default in STATA, we used the observed information matrix to calculate 95% confidence
intervals. In the FE model, each sibling’s score on the outcome variables (externalizing and
internalizing behaviors) was subtracted from the average scores of all siblings in his/her
Table 3. (Continued)
Use of BZDs and z-hypnotics
3-year sample
No Yes
N = 54,641 N = 440
N % N %
Yes 114 0.2 13 3.2
Maternal opioid use in pregnancy
No 53,558 98.0 392 89.1
Yes 1,083 2.0 48 10.9
Maternal SSRI use in pregnancy
No 54,163 99.1 363 82.5
Yes 478 0.9 77 17.5
Maternal antipsychotic use in pregnancy
No 54,546 99.8 416 94.6
Yes 95 0.2 24 5.4
Maternal triptan use in pregnancy
No 54,120 99.0 426 96.8
Yes 521 1.0 14 3.2
Maternal NSAID use in pregnancy
No 50,871 93.1 367 83.4
Yes 3,770 6.9 73 16.6
Maternal use of paracetamol (acetaminophen)
No use 27,971 54.0 151 35.2
1 pregnancy period 13,933 26.9 124 28.9
2 or 3 pregnancy periods 9,884 19,1 154 25.9
Maternal folic acid supplements in early pregnancy
No 16,250 29.7 124 28.2
Yes 38.391 70.3 316 71.8
Maternal chronic diseased
No 49,282 90.2 361 82.1
Yes 5,359 9.8 79 17.9
SSRI, selective serotonin reuptake inhibitors; NSAID, nonsteroidal anti-inflammatory drug
a Mean score of >2 on the Hopkins Symptom Checklist (SCL-5)
b Measured in pregnancy week 17; defined as ever having three co-occurring symptoms of depression for at least 2 weeks and admitting to sad mood
c Illicit drug use included hashish, amphetamine, ecstasy, cocaine, or heroin
d Chronic disease included asthma, diabetes treated with insulin, Crohn’s disease, arthritis, lupus, epilepsy, multiple sclerosis, or cancer
https://doi.org/10.1371/journal.pone.0181042.t003
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family, and each sibling’s value of the predictor (prenatal exposure to BZDs or z-hypnotics)
was subtracted from the average values of all siblings in his/her family. The new outcome
variables were regressed on the new exposure variables. The sibling FE models thereby con-
trolled for potential bias by unobserved variables that were fixed within families (constant
across siblings), such as shared family environments or genetic transmission of risk (e.g.,
maternal personality and intellectual ability). The effect estimates are within families of sib-
lings, and only siblings discordant on exposure and outcome contributed any information.
Finally, we carried out PS-adjusted FE models to adjust for the potential confounding factors
varying between siblings. All analyses were done using Stata Version 14 (Stata Corporation,
College Station, TX, USA).
Results
In total, 0.8% of the children were exposed to BZDs and z-hypnotics during pregnancy
(N1.5 years = 577 of 71,996; N3 years = 440 of 55,081) (Fig 1).
Internalizing behavior problems
Table 4 shows the results of full cohort (random-effect) and sibling-matched (FE) linear
regression models on internalizing behavior problems predicted by in utero exposure to BZDs
and z-hypnotics, short term, long term, and for BZD-anxiolytics and z-hypnotics separately.
Short-term exposure to BZDs and z-hypnotics was associated with increased internalizing
behavior problems in crude analyses at both 1.5 and 3 years of child age. These effects were
attenuated when accounting for the factors associated with maternal use of BZDs and z-hyp-
notics during pregnancy by PS score adjustment. For long-term exposure, increasing associa-
tions were observed in the sibling-matched models at 1.5 years and were not attenuated after
PS score adjustment. At 3 years, crude effects were observed but decreased and were not signif-
icant in the PS-adjusted model. However, in the analyses on exposure to BZD-anxiolytics spe-
cifically, effect estimates from the sibling-matched model on internalizing behavior remained
elevated after adjustment at both 1.5 and 3 years. For z-hypnotics, crude increased internaliz-
ing behavior problems were attenuated after adjusting for PS scores and familial confounding
in the sibling-matched models.
Externalizing behavior problems
Table 5 shows the results of full cohort (random-effect) and sibling-matched (FE) linear
regression models for externalizing behavior outcomes predicted by in utero exposure to BZDs
and z-hypnotics, short term, long term, and for BZD-anxiolytics and z-hypnotics separately.
In crude analyses of short-term exposure to BZDs and z-hypnotics, a small increase in exter-
nalizing behavior problems was observed at child age 1.5 years, with increasing effect estimates
for long-term exposure. Taking PS scores into account, all effects on externalizing behavior
problems were attenuated. No effects were observed for externalizing behavior problems in
the sibling-matched models for short-term and long-term exposure, accounting for familial
confounding, at child age 1.5 or 3 years. In stratified analyses, crude associations with external-
izing behavior were observed at 3 years for BZD-anxiolytics and 1.5 years for z-hypnotics.
These associations were attenuated when accounting for PS score and familial confounding in
the sibling-matched models. At 3 years of age, a beneficial effect of z-hypnotic exposure on
externalizing behavior problems was observed after PS score adjustment.
Prenatal exposure to benzodiazepines and child internalizing problems
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Discussion
In this large prospective follow-up study including siblings discordantly exposed to BZDs or z-
hypnotic drugs, we found that prenatal long-term exposure to BZDs or z-hypnotics was associ-
ated with increased internalizing behavior problems among children aged 1.5 years. Of impor-
tance, when studied separately, BZD-anxiolytics exposure was associated with increased
Table 4. Full cohort and sibling-matched linear regression models: Parameters for differences in internalizing behavior score predicted by in
utero exposure to BZDs and z-hypnotics.
Internalizing behavior
1.5 years 3 years
N β (95% CI) N β (95% CI)
Any BZDs and z-hypnotics
Short terma
Crude cohort sample (re) 71,649 0.12 (0.06, 0.19) 54,741 0.18 (0.10, 0.25)
PS-adjusted cohort sample (re)b 60,964 0.07 (0.001, 0.14) 47,767 0.08 (-0.02, 0.16)
PS-adjusted sibling sample (re) b 18,193 0.12 (-0.01, 0.25) 13,199 0.15 (-0.01, 0.29)
Sibling-matched sample (fe) 19,397 0.10 (-0.08, 0.29) 13,711 0.12 (-0.07, 0.32)
PS-adjusted sibling-matched sample (fe) c 18,193 0.13 (-0.06, 0.32) 13,199 0.12 (-0.08, 0.32)
Long terma
Crude cohort sample (re) 71,649 0.11 (-0.03, 0.24) 54,741 0.21 (0.06, 0.36)
PS-adjusted cohort sample (re) b 60,964 0.01 (-0.13, 0.15) 47,767 0.04 (-0.12, 0.20)
PS-adjusted sibling sample (re) b 18,193 0.21 (-0.07, 0.49) 13,199 0.06 (-0.25, 0.36)
Sibling-matched sample (fe) 19,397 0.46 (0.08, 0.85) 13,711 0.21 (-0.19, 0.62)
PS-adjusted sibling-matched sample (fe) c 18,193 0.60 (0.17, 0.95) 13,199 0.15 (-0.26, 0.56)
Stratified analyses on drug groupsd
BZD-anxiolytics
Crude cohort sample (re) 71,649 0.09 (0.003, 0.17) 54,741 0.24 (0.14, 0.34)
PS-adjusted cohort sample (re) b 60,964 0.05 (-0.04, 0.14) 47,767 0.13 (0.03, 0.24)
PS-adjusted sibling sample (re) b 18,193 0.24 (0.07, 0.41) 13,199 0.23 (0.03, 0.43)
Sibling-matched sample (fe) 19,397 0.26 (0.02, 0.49) 13,711 0.36 (0.17, 0.55)
PS-adjusted sibling-matched sample (fe) c 18,193 0.25 (0.01, 0.49) 13,199 0.26 (0.002,0.52)
Z-hypnotics
Crude cohort sample (re) 71,649 0.14 (0.05, 0.24) 54,741 0.15 (0.05, 0.25)
PS-adjusted cohort sample (re) b 60,964 0.05 (-0.05, 0.15) 47,767 0.02 (-0.09, 0.13)
PS-adjusted sibling sample (re) b 18,193 0.01 (-0.17, 0.19) 13,199 0.03 (-0.17, 0.23)
Sibling-matched sample (fe) 19,397 -0.05 (-0.32, 0.22) 13,711 0.10 (-0.10, 0.30)
PS-adjusted sibling-matched sample (fe) c 18,193 0.02 (-0.26, 0.30) 13,199 0.05 (-0.24, 0.35)
CI, confidence interval; re, random effects; fe, fixed effects; PS: propensity score. Effect sizes (β) for all outcomes should be interpreted as the increase in
terms of standard deviations in the outcome variable (Cohen’s d) in exposed children (reference group: unexposed).
a Three pregnancy periods were defined: gw 0–13, 14–29, 30–birth. Short-term use was defined as reported use in one pregnancy period only. Long-term
use was defined as reported use in two or more pregnancy periods.
b Adjusted for the propensity for taking BZDs and z-hypnotics during pregnancy, conditional on maternal age, formal education, marital status, pre-
pregnancy BMI, parity, smoking, or alcohol use during pregnancy, presence of symptoms of anxiety/depression at gw 17 and/or gw 30, lifetime history of
major depression, sleep problems, use of illicit drugs, chronic disease, use of folic acid supplements, and use of other medications during pregnancy
(opioids, SSRIs, antipsychotics, triptans, NSAIDs, paracetamol).
c Adjusted for the propensity for taking BZDs and z-hypnotics during pregnancy, conditional on maternal age, parity, alcohol use during pregnancy,
presence of symptoms of anxiety/depression gw 17 and/or gw 30, lifetime history of major depression, sleep problems, use of illicit drugs, use of folic acid
supplements, and use of other medications during pregnancy (opioids, SSRIs, antipsychotics, triptans, NSAIDs, paracetamol).
d Including both short- and long-term exposure.
https://doi.org/10.1371/journal.pone.0181042.t004
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internalizing problems at both 1.5 and 3 years of follow-up while z-hypnotic exposure was not
associated with any adverse outcomes.
These findings are in line with previous studies reporting delayed mental functioning up to
the age of 1.5 years after exposure to BZDs [17, 35, 36]. Viggedal et al. observed reduced “per-
sonal-social behavior” abilities at child age 1.5 years but found that externalizing problems
Table 5. Full cohort and sibling-matched linear regression models for externalizing behavior predicted by in utero exposure to BZDs and z-
hypnotics.
Externalizing behavior
1.5 years 3 years
N β (95% CI) N β (95% CI)
Any BZDs and z-hypnotics
Short terma
Crude cohort sample (re) 71,872 0.08 (0.003, 0.15) 54,709 0.03 (-0.06, 0.12)
PS-adjusted cohort sample (re) b 61,537 0.04 (-0.04, 0.12) 47,741 -0.03 (-0.13, 0.06)
PS-adjusted sibling sample (re)b 18,248 0.09 (-0.06, 0.25) 13,191 0.001 (-0.19, 0.19)
Sibling-matched sample (fe) 19,277 0.02 (-0.19, 0.22) 13,701 -0.16 (-0.40, 0.08)
PS-adjusted sibling-matched sample (fe)c 18,248 0.02 (-0.19, 0.23) 13,191 -0.15 (-0.76, 0.25)
Long terma
Crude cohort sample (re) 71,872 0.22 (0.07, 0.37) 54,709 0.19 (-0.05, 0.32)
PS-adjusted cohort sample (re)b 61,537 0.12 (-0.05, 0.28) 47,741 0.09 (-0.10, 0.28)
PS-adjusted sibling sample (re)b 18,248 0.20 (-0.13, 0.53) 13,191 0.13 (-0.25, 0.51)
Sibling-matched sample (fe) 19,277 0.02 (-0.41, 0.44) 13,701 -0.26 (-0.40, 0.08)
PS-adjusted sibling-matched sample (fe)c 18,248 -0.03 (-0.46, 0.40) 13,191 -0.25 (-0.76, 0.25)
Stratified analyses on drug groups d
BZD-anxiolytics
Crude cohort sample (re) 71,872 0.06 (-0.03, 0.16) 54,709 0.13 (0.01, 0.24)
PS-adjusted cohort sample (re)b 61,537 0.06 (-0.05, 0.16) 47,741 0.07 (-0.05, 0.20)
PS-adjusted sibling sample (re)b 18,248 0.06 (-0.14, 0.25) 13,191 0.31 (0.06, 0.56)
Sibling-matched sample (fe) 19,277 -0.02 (-0.28, 0.25) 13,701 0.07 (-0.24, 0.39)
PS-adjusted sibling-matched sample (fe)c 18,248 -0.04 (-0.31, 0.23) 13,191 0.16 (-0.17, 0.48)
Z-hypnotics
Crude cohort sample (re) 71,872 0.12 (0.02, 0.23) 54,709 0.01 (-0.11, 0.13)
PS-adjusted cohort sample (re)b 61,537 0.04 (-0.07, 0.15) 47,741 -0.08 (-0.22, 0.05)
PS-adjusted sibling sample (re)b 18,248 0.08 (-0.13, 0.29) 13,191 -0.22 (-0.47, 0.04)
Sibling-matched sample (fe) 19,277 -0.05 (-0.35, 0.24) 13,701 -0.45 (-0.80, 0.10)
PS-adjusted sibling-matched sample (fe)c 18,248 -0.03 (-0.34, 0.28) 13,191 -0.52 (-0.87, -0.15)
CI, confidence interval; re, random effects; fe, fixed effects; PS: propensity score. Effect sizes (β) for all outcomes should be interpreted as the increase in
terms of standard deviations in the outcome variable (Cohen’s d) in exposed children (reference group: unexposed).
a Three pregnancy periods were defined: gw 0–13, 14–29, 30–birth. Short-term use was defined as reported use in one pregnancy period only. Long-term
use was defined as reported use in two or more pregnancy periods.
b Adjusted for the propensity for taking BZDs and z-hypnotics during pregnancy, conditional on maternal age, formal education, marital status, pre-
pregnancy BMI, parity, smoking, or alcohol use during pregnancy, presence of symptoms of anxiety/depression at gw 17 and/or gw 30, lifetime history of
major depression, sleep problems, use of illicit drugs, chronic disease, use of folic acid supplements, and use of other medications during pregnancy
(opioids, SSRIs, antipsychotics, triptans, NSAIDs, paracetamol).
c Adjusted for the propensity for taking BZDs and z-hypnotics during pregnancy, conditional on maternal age, parity, alcohol use during pregnancy,
presence of symptoms of anxiety/depression gw 17 and/or gw 30, lifetime history of major depression, sleep problems, use of illicit drugs, use of folic acid
supplements, and use of other medications during pregnancy (opioids, SSRIs, antipsychotics, triptans, NSAIDs, paracetamol).
d Including both short- and long-term exposure.
https://doi.org/10.1371/journal.pone.0181042.t005
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such as hyperactivity or attention problems were not significantly different from controls [17].
This result is in line with our finding that internalizing, not externalizing, problems were
reported. Moreover, our study showed effects up to 3 years of age for BZD-anxiolytics. The
only previous study looking at child behavior outcomes beyond the age of 1.5 years found no
effects on behavior reported at the ages of 9–10 years [18]. However, no evaluation of internal-
izing behavior was reported, and the sample consisted of 15 exposed children, limiting the sta-
tistical power to detect effects of exposure [18]. It is therefore unclear whether the lack of
behavior problems at school age was due to diminishing symptoms, crude measures failing to
capture internalizing problems, or low statistical power to detect effects. More prospective fol-
low-up studies with larger sample sizes and measures of internalizing behavior are required to
determine the stability of increased internalizing problems beyond preschool age for specific
drug groups.
Of note, small associations between z-hypnotic exposure and internalizing behavior prob-
lems in the child were attenuated in adjusted analyses taking the indication for use into
account. We found no increase in internalizing or externalizing problems in the sibling-
matched FE models at any time point for children exposed to z-hypnotic drugs. In contrast,
prenatal exposure to z-hypnotics was associated with less externalizing behavior problems at 3
years of age in the sibling-matched analyses. It is possible that using z-hypnotics to reduce
sleep problems in pregnancy is beneficial for the child. To our knowledge, no previous study
has examined potential long-term effects for the child of prenatal z-hypnotic exposure on
behavioral outcomes, and the potential beneficial association between exposure to z-hypnotics
and behavioral effects would need to be confirmed by more studies before any conclusions can
be made regarding the long-term safety.
The present study has a number of strengths. It uses data from a population-based sample
with the possibility of following prospectively more than 400 children prenatally exposed to
BZDs and z-hypnotics and a large control group. The richness of the information available
enables the opportunity to adjust for many potential confounding factors, including indication
for use, which is often not available in conventional studies. Maternal use of BZDs is related to
substance abuse and psychiatric problems in the mother [37]. Of importance, the sibling-
matched design has a number of advantages in controlling for family factors that are difficult to
measure and control for in conventional cohort designs. The intra-class correlation across
pregnancies for the outcomes are 0.35 (internalizing) and 0.41 (externalizing) (both P< 0.001)
[38], showing that stable factors across pregnancies are potentially strong confounders. Because
socioeconomic or genetic factors are likely to confound an association between maternal psy-
chotropic medication use during pregnancy and adverse behavioral outcomes in the child, lim-
iting this type of confounding is an important strength.
The study also has some limitations. First, the sibling-controlled design does not rule out
factors that vary between siblings, correlate with exposure within families, or correlate with the
outcome [39, 40]. The inclusion of an estimated PS in the sibling analyses accounting for the
observed factors shown to be associated with BZD and z-hypnotics use helped control for these
factors in the current study. Although reported use of illicit drugs and substance use were con-
trolled for, we cannot rule out confounding by more complex misuse not reported in the ques-
tionnaires. Second, the design is sensitive to measurement unreliability. Measurement error in
the exposure might lead to an underestimation of the effects [41]. Moreover, the sample size
was not large enough to perform analyses for specific trimesters or on single drugs instead of
drug groups in a sibling-controlled design. For the same reason, stratified analyses on child
gender were not possible, and gender-specific effects could therefore not be explored. The
agreement between self-report and dispensed drugs registered in the Norwegian Prescription
Database (NorPD) for drugs used intermittently, such as BZD-anxiolytics and z-hypnotics, is
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lower than for drugs used chronically [42]. This could be because users of BZDs and hypnotics
often already have the medications available from previous dispensing. More women reporting
BZDs in MoBa were found with a prescription in the NorPD when a longer pre-pregnancy
observation period was included [43]. In a study based on a linkage between the MBRN and
the NorPD including all women giving birth in Norway, 1.5% were reported to use BZDs. In
MoBa, only 0.8% reported use, indicating inclusion of healthier women in that study, which
may limit the generalizability of the current findings. However, even though estimates of fre-
quencies can be biased due to selective participation, exposure–outcome associations have not
previously differed between MoBa participants and the general population [44]. Gustavson
et al. demonstrated using Monte Carlo simulation studies that association estimates are gener-
ally quite robust against selective participation even when the frequency estimates are biased
[45, 46].
In conclusion, our results indicate that prenatal exposures to BZDs influence internalizing
problems in children. Exposure to BZD-anxiolytic or z-hypnotic medications was not associ-
ated with increased externalizing problems. Exposure to BZD-anxiolytics, however, was asso-
ciated with increased internalizing problems in the child, lasting up to 3 years of age. These
findings could not be explained by shared familial confounding, reported indication for use,
or other measured confounding factors, but residual unmeasured confounding cannot be
ruled out.
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